Illumina's SpliceAI2 AI model finds 17% more disease-related genetic variants, doubling variant detection in genomics.

Illumina has launched SpliceAI2, an advanced AI model that improves identification of disease-relevant splice genetic variants by 17% compared to previous models. This breakthrough aids rare disease research, hereditary cancer testing, and drug discovery by better predicting the functional impact of genetic variations. SpliceAI2, part of Illumina's BioInsight AI Lab suite, helps researchers interpret complex genomic data more accurately, enabling detection of twice as many biologically impactful variants. The model is accessible through Illumina's BioInsight applications, supporting faster discovery and precision medicine advancements.

As of Oct 08, 2026 20:12 WIB, Illumina, Inc. (ILMN) shares are priced at USD 265.02 on Pluang, showing a 1.02% decline in the last day. The stock's market capitalization stands at $40.43 billion with a trading volume of 2,948,626 shares. Despite the recent dip, the typical holding period on Pluang is relatively long at 83 days, indicating steady investor interest.